Pharma/Biotech Update: Biogen Idec’s Hemophilia A Drug Approved
June 9, 2014; Posted by: WeBleed staff
Eloctate, a long lasting hemophilia A drug developed by Biogen Idec, gets FDA approval in the United States.
Great news to report from this past weekend. Those living with hemophilia A, or factor VIII deficiency, now have another option for their pharmaceutical care. Coming off the release of their hemophilia B drug, Alprolix, Biogen Idec received official approval from the United States Food and Drug Administration for their newest hemophilia product – Eloctate. Over the years there has been buzz coming out of the Biogen Idec of new research and development incorporating fc fusion proteins. With this technology, scientists and medical personnel have been able to create longer lasting hemophilia products.
The factor VIII molecule is so large that up until a few years ago, a long lasting hemophilia factor medication for hemophilia A patients was only a pipe dream – today it is a reality due to advances in technology and the science behind creating new factor products.
“The proven ability of Eloctate to provide protection from bleeding episodes with prolonged circulation marks the first significant hemophilia A treatment advance in more than 20 years,” Biogen Idec CEO George Scangos stated via a release through FierceBiotech. “As a company deeply committed to improving the lives of people with hemophilia, we are excited to bring this important innovation to those living with hemophilia A.”
It is always great to see new bleeding disorders treatments and medications on the market that give more options to those with a rare, chronic disorder like hemophilia. As stated in earlier Pharma/Biotech updates, both Bayer Pharmaceuticals and Novo Nordisk also have longer lasting hemophilia drugs currently in development. The future continues to look bright for the hemophilia community.
Photo Credit – Biogen Idec
webleed.org – your source for bleeding news!
